Charles River Laboratories is predicting 2025 to be as tough as last year for CDMOs as pharma customers continue to cut costs ...
Nippon Shinyaku pays $110M upfront to Regenxbio for US/Asia rights to RGX-121 and RGX-111 gene therapies for ...
Private investment firm Bridgewest is combing its Australia-based biologics CDMO BioCina and its sterile injectable ...
The top three pharmacy benefit managers hiked the prices of dozens of 'specialty' generic drugs, some by more than 1000% of ...
Daiichi Sankyo is spending $132.5 million to buy an antibody outright that it had already licensed from Glycotope.
IgA1 reduction in 4 hours, outperforming Vertex's povetacicept and Otsuka's sibeprenlimab. Plans for Phase 3 in IgAN.
For as long as I’ve been a healthcare reporter, the JP Morgan Healthcare Conference has served as a newsy way … Get ...
Anavex Life Sciences is back with more data for a pill that it’s looking to get approved in a variety of neurodegenerative ...
XO Health launches health plan in 4 cities, offering employers alternative coverage with fixed-price care packages and ...
Moderna is slashing its 2025 revenue estimate by $1 billion and expanding cost-cutting measures as it continues to struggle ...
In the 10th megaround of 2025, Umoja Biopharma has banked $100 million in a Series C fundraise with an eye to advancing its pipeline of in vivo CAR-T cell therapies for cancer and autoimmune diseases.
Former FDA Commissioner Scott Gottlieb said Robert F. Kennedy Jr. should not lead the US health agencies, underscoring the risk of further eroding faith in vaccines.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback